Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells: Role of cGMP in the regulation of the plasminogen system

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 11, 1998, Pages 1771-1779

  Bouchie, Julie L ^a   Hansen, Hans ^a   Feener, Edward P ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

Angiotensin II; Natriuretic factors; Nitric oxide; Plasminogen activator inhibitor; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; DACTINOMYCIN; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR;

ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA INTIMA; ARTICLE; ATHEROGENESIS; DOSE RESPONSE; MOLECULAR STABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; RAT; TRANSCRIPTION REGULATION; VASCULAR SMOOTH MUSCLE;

EID: 0031797874     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.11.1771     Document Type: Article

References (14)

1. Kwaan HC. The biologic role of components of the plasminogen-plasmin system. Prog Cardiovasc Dis. 1992;34:309-316.
2. Vassalli J-D, Sappino A-P, Belin D. The plasminogen activator/plasmin system. J Clin Invest. 1991;88:1067-1072.
3. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87-115.
4. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature. 1990;346:74-76.
5. Krishnamurti C, Alving BM. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo. Semin Thromb Hemost. 1992;18:67-80.
6. Baricos WH, Cortez SL, EI-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int. 1995;47:1039-1047.
7. 3 binding to vitroneclin. Nature. 1996;383:441-443.
8. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type I is related to insulin resistance. Metabolism. 1993;42:945-949.
9. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104-109.
10. Gruden G, Cavallo-Perin P, Bazzan M, Stella S, Fuolo A, Pagano G. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes. 1994;43:426-429.
11. Gray RP, Yudkin JS, Patterson DL. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br Heart J. 1993;69:228-232.
12. Hamsten A, Walldius G, Szamosi A, Blomback M, Faire U, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
13. Gray RP, Patterson DLH, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arterioscler Thromb. 1993;13:415-420.
14. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 1992;89:6998-7002.